Experimental cell therapy targets tough rheumatoid arthritis
NCT ID NCT07315503
Summary
This is an early, small study to test the safety and initial effects of a new cell therapy called GC012F for people with difficult-to-treat rheumatoid arthritis (RA). It will enroll 9 adults whose RA has not responded well to multiple standard treatments. Researchers will give patients an infusion of their own genetically modified immune cells (CAR-T cells) and closely monitor them for side effects and any changes in their RA symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, China
Conditions
Explore the condition pages connected to this study.